APM
DNTH icon

Avidity Partners Management’s Dianthus Therapeutics DNTH Stock Holding History

Avidity Partners Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$361M Buy
4,208,368
+2,104,184
+100% +$122M 38.62% 1
2025
Q4 		$86.7M Sell
2,104,184
-1,100,000
-34% -$42.6M 25.01% 1
2025
Q3 		$126M Buy
3,204,184
+1,461,282
+84% +$37.3M 28.7% 1
2025
Q2 		$32.5M Buy
1,742,902
+22,000
+1% +$413K 6.47% 4
2025
Q1 		$31.2M Sell
1,720,902
-1,152,098
-40% -$25.4M 5.95% 2
2024
Q4 		$62.6M Sell
2,873,000
-44,231
-2% -$1.14M 6.15% 1
2024
Q3 		$79.9M Hold
2,917,231
– – 4.07% 2
2024
Q2 		$75.5M Buy
2,917,231
+199,677
+7% +$4.8M 3.21% 6
2024
Q1 		$81.5M Buy
2,717,554
+1,500,000
+123% +$32.6M 2.63% 6
2023
Q4 		$12.7M Hold
1,217,554
– – 0.46% 57
2023
Q3 		$16.6M Buy
+1,217,554
New +$15.3M 0.67% 56

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Avidity Partners Management's DNTH Position: Q1 2026 in Review

Avidity Partners Management increased its Dianthus Therapeutics (DNTH) stake by 100% in Q1 2026, buying an estimated $122M and bringing the position to 4,208,368 shares worth $361M. The position accounts for 38.62% of the portfolio, ranked #1.

Avidity Partners Management first reported a position in DNTH in Q3 2023 and has held it in 11 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Avidity Partners Management held 4,208,368 shares of Dianthus Therapeutics worth $361M as of Q1 2026.
  • Avidity Partners Management bought 2,104,184 Dianthus Therapeutics shares in Q1 2026, an estimated $122M.
  • Dianthus Therapeutics made up 38.62% of Avidity Partners Management's portfolio in Q1 2026, its #1 holding.
  • Avidity Partners Management first reported a position in Dianthus Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Avidity Partners Management's 13F filing for Q1 2026, filed 13 May 2026.